

## Special Issue

# Cell Cycle and Cell Cycle Checkpoint Deregulations: From Oncogenic Drivers to Therapeutic Targets

### Message from the Guest Editor

Cell cycle deregulation is a hallmark of cancer. Cell cycle core proteins are frequently mutated in human tumors. Moreover, cancer cells often have defective cell cycle checkpoints; thus, progression along the cycle is permitted also to cells bearing DNA damage or chromosome segregation errors. For this Special Issue we invite original research papers and reviews discussing update information about the normal cell cycle machinery and the mechanisms causing its oncogenic switch. Papers and reviews about the development of novel drugs directed against cell cycle targets are also welcomed. Finally, we encourage the submission of manuscripts focusing on how defects in cell cycle checkpoints, while apparently advantageous for cancer cell uncontrolled proliferation, can be exploited to directly promote cell death or to increase vulnerability to major currently used therapeutics. Looking forward to your contributions.

---

### Guest Editor

Dr. Roberta Visconti

Institute of Experimental Endocrinology and Oncology "G. Salvatore", Italian National Council of Research, Via S. Pansini 5, 80131 Napoli, Italy

---

### Deadline for manuscript submissions

closed (30 September 2020)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/si/36315](https://mdpi.com/si/36315)

*Cancers*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)